The gastrointestinal hormone PYY 3-36 is a preferential Y2 neuropeptide Y (NPY) receptor agonist. Recent evidence indicates that PYY 3-36 acts on central dopaminergic pathways, but its influence on dopamine-dependent behaviours remains largely unknown. We therefore explored the effects of peripheral PYY 3-36 treatment on the behavioural responses to novelty and to dopamine-activating drugs in mice. In addition, we examined whether PYY 3-36 administration may activate distinct dopamine and γ-aminobutyric acid (GABA) cell populations in the mesoaccumbal and nigrostriatal pathways. We found that i.p. PYY 3-36 injection led to a dose-dependent increase in novel object exploration. The effective dose of PYY (1 μg/100 g body weight) also potentiated the locomotor reaction to the indirect dopamine receptor agonist amphetamine and increased stereotyped climbing/leaning responses following administration of the direct dopamine receptor agonist apomorphine. PYY 3-36 administration did not affect activity of midbrain dopaminergic cells as evaluated by double immuno-enzyme staining of the neuronal early gene product c-Fos with tyrosine hydroxylase. PYY 3-36 did, however, lead to a marked increase in the number of cells co-expressing c-Fos with glutamic acid decarboxylase in the nucleus accumbens and caudate putamen, indicating activation of GABAergic cells in dorsal and ventral striatal areas. Our results support the hypothesis that acute administration of the preferential Y2 receptor agonist PYY 3-36 modulates dopamine-dependent behaviours. These effects do not seem to involve direct activation of midbrain dopamine cells but instead are associated with neuronal activation in the major input areas of the mesoaccumbal and nigrostriatal pathways.
Introduction
Peptide tyrosine-tyrosine (PYY) is a member of the PP-fold family of peptides, which further includes neuropeptide Y (NPY) and pancreatic polypeptide (PP) (Berglund et al., 2003) . These peptides exert their biological functions through binding to distinct subclasses of NPY receptors, which are commonly referred to as Y1, Y2, Y4, Y5 and Y6 receptors (Schloegl et al., 2011) . Two endogenous forms of PYY have been identified, namely PYY 1-36 and PYY (Grandt et al., 1994) . PYY 3-36 is generated from PYY 1-36 by cleavage of two amino acids through the actions of the enzyme dipeptidyl peptidase-IV (Mentlein et al., 1993) . PYY 3-36 is the major circulating form of PYY (Grandt et al., 1994) . Following systemic PYY 3-36 administration, the peptide effectively crosses the blood-brain barrier (Nonaka et al., 2003) and acts as a selective Y2 receptor agonist (Grandt et al., 1994) .
The Y2 receptor is mainly localized at presynaptic sites and is believed to mediate a potent negative feedback inhibition of the release of NPY (King et al., 1999; Smith-White et al., 2001) . Immunohistochemical studies suggest that the Y2 receptor is abundantly expressed in various brain regions, including brain stem areas and structures of the limbic system such as the nucleus accumbens (NAc), the amygdala (Amy), the hypothalamus (Hyp) and the hippocampus (Hpc) (Stanic et al., 2006) . Consistent with this receptor distribution, peripheral administration of the Y2 receptor agonist PYY in rodents has been show to induce neuronal activation in multiple brain areas, as evidenced by immunohistochemical evaluations of the neuronal early gene product c-Fos (Blevins et al., 2008; Stadlbauer et al., 2013a) .
Functional magnetic resonance imaging (fMRI) in humans has further shown that administration of PYY induces neuronal activation in the mesocorticolimbic dopamine pathway (Batterham et al., 2007) . The mesocorticolimbic dopamine pathway arises from the ventral tegmental area (VTA) and projects to the medial and ventral parts of the caudate putamen (CPu), NAc, Hpc, Amy and medial prefrontal cortex (mPFC) (Van den Heuvel and Pasterkamp, 2008) . This pathway plays an important role in regulating emotional, attentional and reward-related behaviours (Spanagel and Weiss, 1999; Nieoullon, 2002) and is pivotal for mediating the behavioural responses to drugs of abuse (Kauer and Malenka, 2007) . The second major dopaminergic pathway arises from the substantia nigra (SN) and projects to the CPu, forming the nigrostriatal dopamine pathway ( Van den Heuvel and Pasterkamp, 2008) . It is crucial for the control of voluntary movement and motor stereotypies (Groenewegen, 2003; Langen et al., 2011) .
Attempts to elucidate the physiological roles of PYY have, thus far, almost exclusively focused on the control of food intake and regulation of energy homeostasis (Chandarana and Batterham, 2008; Neary and Batterham, 2009 ). In view of its activating effects on dopaminergic structures (Batterham et al., 2007; Stadlbauer et al., 2013a) , however, it is likely that PYY 3-36 administration may also modulate various other dopamine-dependent behavioural functions. The present study tested this hypothesis by exploring the effects of peripheral PYY 3-36 treatment on the behavioural responses to novelty and dopaminergic drugs of abuse in mice. The former was evaluated by investigating the effects of PYY 3-36 administration on exploration of a novel environment and an unfamiliar object. Possible effects of PYY 3-36 treatment on the sensitivity to dopaminergic drugs were investigated by assessing the animals' behavioural responses to acute challenges with amphetamine (Amph) or apomorphine (Apo). Amph is an indirect dopamine receptor agonist that efficiently stimulates presynaptic dopamine release (Salahpour et al., 2008) . Besides other effects, Amph efficiently stimulates locomotor activity (Robbins and Iversen, 1973; Robinson and Becker, 1986) . Apo is a preferential dopamine D1/D2 receptor agonist that induces dose-dependent effects on locomotor activity and stereotyped behaviours in rodents, including repetitive climbing and leaning (Cabib and Puglisi-Allegra, 1985; Bitanihirwe et al., 2010) . The mesolimbic and nigrostriatal dopamine pathways are key neuronal components regulating the behavioural responses to novelty and dopamine-activating drugs such as Amph and Apo (Creese and Iversen, 1975; Pijnenburg et al., 1975; Strombom, 1976; Subramony, 2006) , and they functionally interact with the numerous brain structures that mediate locomotor and stereotyped behaviours (Groenewegen et al., 1996; Langen et al., 2011) .
We further explored whether PYY 3-36 administration may modulate the activation of distinct dopamine and γ-aminobutyric acid (GABA) cell populations in selected brain areas, to assess possible neuronal mechanisms underlying the anticipated modulation of behavioural responsiveness to novelty and acute dopaminergic drug challenge following peripheral PYY 3-36 treatment. For this purpose, we used double immuno-enzyme staining to study the co-expression of the neuronal early gene product c-Fos with tyrosine hydroxylase (TH) on the one hand, and with the 67-kDa isoform of glutamic acid decarboxylase (GAD67) on the other hand (van der Loos, 2008) . TH is the rate-limiting enzyme of dopamine (and noradrenalin) synthesis and can therefore be used as a dopaminergic marker for the detection of mesencephalic dopamine cells (Bacopoulos and Bhatnagar, 1977) . GAD67 is expressed by the majority of GABAproducing cells and is therefore a suitable marker to detect GABAergic neurons (Esclapez et al., 1994) . Dopaminergic and GABAergic cell activation was studied in the VTA and SN, to explore neuronal activation in the two relevant dopaminergic midbrain areas. Neuronal activation was further investigated in the primary input stations of the mesolimbic and nigrostriatal pathways, namely the NAc and CPu (Groenewegen et al., 1996; Van den Heuvel et al., 2008) . In addition, GABAergic cell activation was analysed in the ventral pallidum (VP) and the lateral globus pallidus (LGP), which receive major inputs from the NAc and CPu, respectively (Groenewegen, 2003) .
Method

Animals
Male C57BL6 mice (Charles River, Germany) were used throughout the study. They were obtained at the age of 8-10 wk. Testing began after 2 wk of acclimatization to the new animal holding room, which was temperature and humidity controlled (21 ± 2°C, 55 ± 5%) with a 12-h light, 12-h dark cycle (lights off: 7 am). The animals had ad libitum access to water and food (Kliba 3436, Provimi Kliba NAFAG, Kaiseraugst, Switzerland) and were kept in groups of 3-5 animals per cage throughout all experimentation. Behavioural testing was always carried out during the dark phase of the lighting cycle and involved transient exposure of the animals to a dimly lit room. Each individual pharmacological or immunohistochemical test was performed using a new cohort of behaviourally and drug naïve animals, in order to avoid confounds arising from multiple psychostimulant drug administration. The numbers of animals used in each test are provided in the corresponding figure legends.
All procedures described in the present study were approved by the Cantonal Veterinary Office of Zurich and are in agreement with the principles of laboratory animal care in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 86-23, revised 1985) .
(PBS) containing appropriate amounts of bovine serum albumin (BSA) (Stadlbauer et al., 2013a) . Vehicle-treated (VEH) animals only received PBS containing equal amounts of BSA. In the first experiment, PYY 3-36 was injected at a dose of 0.25 (=PYY-0.25), 0.5 (=PYY-0.5), and 1 (=PYY-1) μg/100 g body weight (BW). In all subsequent experiments, PYY 3-36 was injected at a dose of 1 μg/100 g BW (=PYY-1) because it was the minimal effective dose in the first experiment. Systemic administration of PYY 3-36 at 1 μg/100 g BW has previously been shown to affect a number of behavioural functions in C57BL6 mice, including social interaction and prepulse inhibition of the acoustic startle reflex (Stadlbauer et al., 2013b) . Our pilot studies confirmed that acute treatment with PYY 3-36 at the highest dose (PYY-1) did not cause aversion to a novel flavour (saccharine) in a standard conditioned taste aversion test ( Supplementary Fig 1) . All solutions were freshly prepared on the day of testing and administered i.p. using an injection volume of 5 ml/kg.
Exploratory behavioural response to novelty
Exploratory behavioural responses to novelty were assessed using a modified open field exploration test (Kulak et al., 2012) . The test apparatus is fully described in the Supplementary Methods. The open field exploration test consisted of two phases: in the first phase the animals received an injection of PYY 3-36 at the selected dosages (0.25, 0.5, or 1 μg/100 g BW) or VEH, and were then placed into the open field arena and left undisturbed for 30 min, during which they could freely explore the open field arena. This test measures the exploratory behavioural response to a novel environment and assesses locomotor habituation over time (Kulak et al., 2012) . For the purpose of data collection, the arena was conceptually partitioned into two zones: a centre zone (measuring 15 × 15 cm) in the middle of the arena and a peripheral zone occupying the remaining area. Centre zone activity was measured to index aspects of anxiety-like behaviour during exploration of novel environments (Belzung and Griebel, 2001 ). The second phase of the test (i.e. the novel object exploration test) commenced immediately after phase one without removing the animals from the open field apparatus. For the novel object exploration test, a novel object (acrylic Falcon tube filled with tap water and sealed with a green cap; 3 cm in diameter, 11 cm height) was placed into the central area of the open field and stabilized with transparent tape. Locomotor activity in the entire open field arena was recorded for 15 min. In addition, time spent in, and numbers of entries into, the centre area containing the novel object were also recorded in order to index exploration of the novel object.
Locomotor reaction to acute amphetamine challenge
The effects of PYY 3-36 pre-treatment on the behavioural sensitivity to Amph were assessed by measuring locomotor activity in an open field apparatus, as described previously Vuillermot et al., 2011) . The open field apparatus was identical to the one described above. At the beginning of a test session, the animals were placed into the centre of the corresponding open field arena. Animals were allowed to explore the arena freely for 30 min, which served to habituate the animals to the test apparatus and to measure basal locomotor activity. Animals were then quickly removed from the open field and received an injection of 1 μg/100 g BW (=PYY-1) or VEH. They were then placed into a waiting box containing home cage sawdust bedding for 5 min. Subsequently, animals were injected with Amph (2 mg/kg, i.p.) or saline (Sal) solution and were immediately placed back to the appropriate arena again. The Amph solution was prepared according to the procedures described in detail in the Supplementary Methods. The locomotor reactions to the acute drug or Sal challenges were then recorded for a total of 60 min.
Stereotyped responses to acute apomorphine treatment
Acute Apo treatment was used to assess the effects of PYY 3-36 pre-treatment on dopamine-related stereotyped behaviours. Animals were injected with 1 μg/100 g BW PYY 3-36 (=PYY-1) or VEH and then placed in a sawdust-covered waiting box for 15 min, after which they were injected with Apo (5 mg/kg, s.c.) or corresponding vehicle (VitC) solution and immediately placed into a wire mesh cylinder test apparatus. The preparation of the Apo solution and test apparatus is fully described in the Supplementary Methods. The dependent variables of primary interest were horizontal locomotor activity and presence of repetitive climbing and leaning (see Supplementary Methods). For the purpose of the analysis, leaning and climbing were combined to obtain the stereotypic score (Bitanihirwe et al., 2010) .
Double immuno-enzyme staining
To assess the effects of PYY 3-36 treatment on neuronal activation, we used double immuno-enzyme staining (van der Loos, 2008) to measure the expression of the neuronal early gene product c-Fos in dopaminergic and GABAergic cells. For this purpose, animals were first habituated to a 5-h fasting period (starting 2 h after dark onset) on 4 consecutive d (Stadlbauer et al., 2013a) . On the fifth day, animals were fasted for 3 h prior to treatment with 1 μg/100 g BW PYY 3-36 (=PYY-1) or VEH treatment as described above. 2 h after PYY or VEH treatment, the animals were deeply anaesthetized and perfused using procedures described in the Supplementary Methods. The brains were then processed for the double immuno-enzyme staining as fully described in the Supplementary Methods.
Unbiased stereological estimations
The numbers of immunoreactive cells positive for c-Fos, TH and GAD67 alone, as well as cells co-expressing c-Fos with TH or c-Fos with GAD67, were determined by unbiased stereological estimations using the optical fractionator method (Gundersen et al., 1988) as described in the Supplementary Methods. Stereological estimations were performed in the NAc (Bregma +1.60 to +0.98 mm), CPu (Bregma +1.34 to +0.14 mm), VP (+0.62 to −0.10 mm), LGP (−0.22 to −0.94 mm), SN (Bregma −2.80 to −3.64 mm) and VTA (Bregma −2.92 to −3.64 mm) (see Supplementary Methods).
Statistical analyses
All data were analysed by parametric analysis of variance (ANOVA) followed by Fisher's least significant difference (LSD) post-hoc comparisons whenever appropriate. Statistical significance was set at p < 0.05. All statistical analyses were performed using the statistical software StatView (version 5.0).
In the first phase of the open field test, total distance moved in the entire open field, time spent in the centre zone, and number of centre zone entries were expressed as a function of 1-min bins and analysed using a 4 × 30 (PYY pre-treatment × bins) ANOVA. The same dependent variables were also expressed as a function of 1-min bins and analysed using a 4 × 15 (PYY pretreatment × bins) ANOVA for the second phase of the open field test, which included a novel object in the centre zone. In the Amph sensitivity test, the total distance moved was expressed as a function of 5-min bins and was analysed using a 2 × 2×6 (PYY pre-treatment × Amph condition × bins) ANOVA for the initial habituation phase and a 2 × 2 × 12 (PYY pre-treatment × Amph treatment × bins) ANOVA for the subsequent test phase. In the APO sensitivity test, the horizontal distance moved was expressed as a function of 5-min bins and analysed using a 2 × 2 × 6 (PYY pre-treatment × Apo treatment × bins) ANOVA, and the stereotyped behavioural response (i.e. combined leaning and climbing) was expressed as per cent time leaning/climbing (%) and analysed using a 2 × 2 × 6 (PYY pre-treatment × Apo treatment × bins) ANOVA. All immunohistochemical data were analysed using independent Student's t-tests (two-tailed).
Results
PYY 3-36 treatment increases novel object exploration
In the first phase of the open field test, locomotor activity indexed by the distance moved decreased as a function bins (main effect of bins: F(87,986) = 26.94, p < 0.001), reflecting normal locomotor habituation to novel environments. This habituation response was highly similar between VEH and PYY 3-36 animals (Fig. 1a) . Likewise, the four groups did not differ with respect to the centre zone time or frequency (Fig. 1a, c) . ANOVA of these dependent variables did not yield any significant main effects or interactions involving the between-subjects factor of PYY treatment.
After introducing a novel object into the centre zone, however, animals treated with the highest dose of PYY 3-36 (i.e. PYY-1 animals) displayed significantly enhanced locomotor activity in the entire open field compared to VEH-treated animals and animals treated with the lower doses of PYY (Fig. 1b) . ANOVA of the distance moved revealed a significant main effect of PYY treatment (F(3,34) = 4.06, p < 0.05). Subsequent post-hoc comparisons confirmed the significant difference between PYY-1 and VEH (p < 0.05), PYY-0.25 (p < 0.01), and PYY-0.5 (p < 0.01) animals. In addition, PYY-1 animals explored the novel object more frequently than VEH, PYY-0.25, and PYY-0.5 animals (Fig. 1b, d) , as indicated by the significant main effect of PYY in the analysis of number of visits into the object zone (F(3,34) = 5.26, p < 0.01) and time spent in the object zone (F(3,34) = 4.50, p < 0.01). Subsequent post-hoc comparisons verified the significant difference between the PYY-1 and VEH (for both measures p < 0.05), PYY-0.25 (for both measures p < 0.01) and PYY-0. 5 (for both measures p < 0.01) groups. (Fig. 2) .
Acute treatment with Amph generally increased locomotor activity, leading to a significant main effect of bins (F(11,220) = 3.35, p < 0.001) and its interaction with Amph treatment (F(11,220) = 7.79, p < 0.001). Most interestingly, the locomotor-stimulating effect of systemic Amph treatment was significantly enhanced in animals pretreated with 1 μg/100 g BW PYY 3-36 (=PYY-1) relative to VEH pre-treated animals (Fig. 2) , as shown by the significant interaction between PYY pre-treatment × Amph treatment (F(1,20) = 4.26, p < 0.05). Subsequent post-hoc group comparisons confirmed the significant increase in locomotor activity displayed by PYY-1/Amph mice compared with VEH/Amph mice (p < 0.05), PYY-1/Sal mice (p < 0.001), and VEH/Sal mice (p < 0.001) (Fig. 2) . pre-treatment (Fig. 3a) . ANOVA of horizontal distance moved only yielded a significant main effect of Apo (F(1,16) = 64.19, p < 0.001). Exposure to Apo also induced marked stereotyped behaviour in the form of increased leaning and climbing behaviour, as indicated by the significant main effect of Apo treatment (F(1,16) = 39.26, p < 0.001) and its interaction with bins (F(5,80) = 12.25, p < 0.001). While this stereotyped response gradually increased as a function of bins in VEH pre-treated mice, the leaning/climbing score in animals pre-treated with 1 μg/100 g BW PYY 3-36 (=PYY-1) reached 100% as early as 5 min after Apo administration (Fig. 3b) . Hence, PYY 3-36 pre-treatment at 1 μg/100 g BW markedly increased the responsiveness to Apo-induced behavioural stereotypies, as supported by the significant interaction between PYY 3-36 pre-treatment and Apo treatment (F(1,16) = 5.26, p < 0.05). Subsequent post-hoc group comparisons confirmed the significant difference between the PYY-1/Apo and VEH/Apo groups (p < 0.01). In addition, post-hoc comparisons revealed a significant difference between PYY-1/Apo and PYY-1/ VitC or VEH/VitC animals (all p's < 0.001), and between VEH/Apo and PYY-1/VitC or VEH/VitC animals (all p's < 0.001). 
PYY 3-36 treatment does not affect c-Fos expression in midbrain dopamine cells
The double immuno-enzyme staining using VR and VB for red and blue colour, respectively, provided a clear segregation between TH-positive (red) and c-Fos-positive (blue) cells in the ventral midbrain (Fig. 4) . As expected, strong TH immunoreactivity was found in the cytoplasmic and axonal compartments of midbrain dopamine cells, whereas c-Fos immunoreactivity showed a distinct nuclear localization (Fig. 4b) . Consistent with previous stereological estimations (Vuillermot et al., 2010) , the total number of TH-positive cells in the VTA and SNc ranged between 6000 and 9000 cells unilaterally, and these cell counts were highly similar between PYY 3-36 -and VEH-exposed animals (Fig. 4d) . PYY 3-36 treatment at 1 μg/100 g BW (=PYY-1) did not induce c-Fos expression in either the VTA and or the SNc (Fig. 4d) , but it led to a strong increase in c-Fos immunoreactivity in positive control areas, such as the paraventricular nucleus of the hypothalamus (Supplementary Fig S2) . Furthermore, only a minority of c-Fos-positive cells co-localized with TH-expressing cells in the VTA and SNc, regardless of whether animals were exposed to PYY 3-36 at 1 μg/100 g BW or VEH treatment (Fig. 4b, d) . (Fig. 5b) . GAD67 immunoreactivity was largely localized to the cytoplasmic compartments of GABAergic cells, whereas c-Fos immunoreactivity again showed a discrete nuclear localization (Fig. 5b) . Consistent with our TH/c-Fos double immuno-enzyme staining (Fig. 4) , PYY 3-36 treatment at 1 μg/100 g BW (=PYY-1) did not increase c-Fos expression in either the VTA or SNc (Fig. 5d, e) . In contrast, PYY 3-36 administration led to a substantial (>200%) increase in cells immunoreactive for c-Fos in the NAc (t = 7.43, p < 0.001) and CPu (t = 2.64, p < 0.05) (see Fig. 5a, c) . Interestingly, most of the c-Fos-positive cells in the NAc and CPu of PYY 3-36 -treated animals also expressed GAD67, as evident by the significant effect of PYY 3-36 administration on GAD67/c-Fos double-labelled cell counts in these regions (NAc: t = 6.01, p < 0.001; CPu: t = 2.50, p < 0.05) (see Fig. 5c ). PYY 3-36 treatment did not affect GAD67 expression per se in any of the brain areas investigated (Fig. 5) .
PYY 3-36 treatment induces c-Fos expression in ventral pallidal GABAergic cells VR (red) and VB (blue) double immuno-enzyme staining also distinguished GAD67-positive (red; cytoplasmic localization) from c-Fos-positive (blue; nuclear localization) cells in the VP (Fig. 6a, c) . PYY 3-36 administration led to a ∼100% increase in cells immunoreactive for c-Fos in the VP (t = 2.58, p < 0.05; Fig. 6b ), whereas c-Fos expression was generally largely undetectable in the LGP (see Supplementary Fig S3) . The vast majority of c-Fos-positive cells in the VP of PYY 3-36 -treated animals also expressed GAD67, as evident by the significant effect of PYY 3-36 administration on GAD67/c-Fos doublelabelled cell counts in this region (t = 2.89, p < 0.05; see Fig. 6b ). PYY 3-36 treatment did not affect GAD67 expression per se in the VP (Fig. 6b) .
Discussion
The present data provide the first direct evidence for a modulating effect of peripheral administration of the Y2 receptor agonist PYY 3-36 on the behavioural responses to novelty and dopamine-activating drugs. The former effect was evident by increased exploration of a novel object in response to i.p. PYY 3-36 , whereas the latter was manifested by enhanced locomotor reactions to acute Amph treatment and increased stereotyped responses to acute Apo challenge after PYY 3-36 pre-treatment. It is important to emphasize that the chosen dose of PYY 3-36 did not cause aversion to a novel taste (saccharine) in a standard conditioned taste aversion test, suggesting that the observed behavioural effects were not associated with possible confounds arising from gastric malaise and/or nausea (Halatchev and Cone, 2005) . In further support of this notion, PYY 3-36 treatment in the absence of additional environmental (novel object) or drug (Amph or Apo) exposure did not affect locomotor activity or behavioural stereotypies. Indeed, the locomotor activity scores were highly similar between the PYY 3-36 and VEH groups in the initial phase of the open field test (when no discrete novelty stimulus other than the novel environment was presented), and so were the locomotor activities between PYY 3-36 /Sal and VEH/Sal animals in the Amph sensitivity test. Furthermore, horizontal distance moved and stereotyped behaviours were highly comparable between PYY 3-36 /VitC and VEH/VitC animals in the Apo sensitivity test. These results thus indicate that peripheral PYY 3-36 treatment interacts with salient stimuli (such as a novel object) or with indirect (Amph) and direct (Apo) dopamine receptor agonists to modulate dopamine-dependent behavioural functions, at least with respect to locomotor activity and behavioural stereotypies.
To what extent can changes in innate anxiety-like behaviours account for the potentiated exploratory response to the novel object in PYY 3-36 -treated animals? We found that PYY 3-36 -and VEH-exposed animals spent very similar amounts of time in the centre zone of the open field during the initial habitation test phase. Activity in the centre zone of the open field test is often taken to index innate anxiety-like behaviour in rodent models when measured under basal conditions, that is, in the absence of additional object presentation (Belzung and Griebel, 2001; Kulak et al., 2012) . We also did not observe any significant effects of PYY 3-36 treatment in other tests assessing innate anxiety-like behaviour such as the elevated plus maze test (Stadlbauer et al., 2013b) . It therefore seems unlikely that the PYY 3-36 -induced increase in novel object exploration may be confounded by changes in innate anxiety-related behaviours.
Alternatively, enhanced novel object exploration in PYY 3-36 -treated animals may be related to changes in incentive salience, which is typically referred to as a motivational attribute that increases the attractiveness of a given stimulus and promotes approach behaviour towards it (Berridge and Robinson, 1998) . Research in rats suggests that there is a positive correlation between the amount of novelty seeking and incentive salience attribution to reward-associated cues (Beckmann et al., 2011) . Dopaminergic mechanisms in general, and increased accumbal dopaminergic activity in particular, seem to be critical in regulating the perception and processing of salient stimuli (Berridge and Robinson, 1998; Wise, 2004) . For example, manipulations increasing and decreasing dopaminergic activity in the NAc, receptively, enhance and reduce exploratory activities towards novel stimuli (Rebec et al., 1997; Peters et al., 2007; Fukushiro and Frussa-Filho, 2011) . Furthermore, rats displaying increased novelty-seeking exhibit a greater behavioural sensitivity to the indirect dopamine receptor agonist cocaine (Beckmann et al., 2011) . Here we observed a similar association between novelty seeking (in the novel object exploration test) and behavioural responsiveness to the indirect dopamine receptor agonist Amph, both of which were increased following PYY 3-36 administration. One possibility is therefore that the PYY 3-36 -induced enhancement of novel object exploration may involve increased dopaminergic activity (in mesolimbic systems), similar to the findings reported by others (Rebec et al., 1997; Peters et al., 2007; Beckmann et al., 2011) . This interpretation is also consistent with previous studies showing that exogenous administration of PYY 3-36 increased the synthesis and release of dopamine in the rat striatum (Adewale et al., 2005 (Adewale et al., , 2007 . Moreover, the locomotor-enhancing effects of low doses of systemic Amph (∼2 mg/kg for mice) typically emerges because of increased dopamine transmission in the NAc (Creese and Iversen, 1975; Pijnenburg et al., 1976) , especially in its shell sub-region (Heidbreder and Feldon, 1998) . Enhanced activation of striatal dopamine receptors has further been related to increased expression of stereotyped behaviours (Arnt et al., 1988; Vasse and Protais, 1989; Bitanihirwe et al., 2010) . Taken together, there is a growing body of evidence suggesting that exogenous PYY 3-36 administration induces neurochemical and behavioural changes reminiscent of a (transient) hyperdopaminergic state.
These presumed dopaminergic mechanisms induced by PYY 3-36 may not necessarily involve direct activation of the mesoaccumbal (VTA to NAc) or nigrostriatal (SNc to CPu) dopamine pathways. Indeed, our TH/ c-Fos double immuno-enzyme staining showed that PYY 3-36 treatment did not induce neuronal activation of TH-positive dopamine cells in the VTA or SNc, which are the two primary midbrain areas containing the majority of dopamine cells in the CNS (Van den Heuvel , 2008) . Furthermore, ex vivo pharmacological studies in rats suggest that exogenous administration of PYY 3-36 can increase dopamine release in striatal slices that are fully disconnected from their major dopaminergic input structures (Adewale et al., 2007) . It thus appears that the pro-dopaminergic effects of PYY 3-36 may involve indirect actions, possibly via a modulation of other neurotransmitter systems that are functionally connected with dopaminergic pathways. Our double immuno-enzyme evaluations of GAD67/ c-Fos co-expression provide some first evidence for this assumption. Consistent with our previous observations in rats (Stadlbauer et al., 2013a) , we found a significant increase in c-Fos in dorsal (CPu) and ventral (NAc) striatal structures in PYY 3-36 -treated animals. Furthermore, PYY 3-36 administration significantly increased c-Fos immunoreactivity in the VP. Perhaps even more important are our results showing that most of the c-Fospositive cells in the NAc, CPu, and VP of PYY 3-36 -treated animals co-localized with GAD67. Hence, even though the peptidergic treatment failed to directly activate dopaminergic cells in the VTA and SNc, it induced a strong activation of GABAergic cells in their primary (NAc and CPu) and secondary (VP) target regions. The marked co-localization of c-Fos and GAD67 in these target regions may not be unprecedented because the majority of striatal neurons in the CPu and NAc are inhibitory GABAergic spiny neurons, which comprise 90-95% of the total neuronal population in striatal areas (Smith and Kieval, 2000; David et al., 2005) . Within the NAc, GABAergic spiny neurons send major output projections to the VP, which is the main target of NAc efferent pathways (Groenewegen et al., 1996) . On the other hand, GABAergic spiny neurons located in the CPu are the primary output neurons sending projections to the external and internal segments of the GP (Groenewegen, 2003) . GABAergic neurons are also abundant in the VP, where they form the main ventral pallidal projection neurons together with cholinergic neurons (Smith et al., 2009) .
Increased neuronal activity especially in the NAc and its main projection site, the VP, may be a relevant mechanism underlying the PYY 3-36 -induced potentiation of dopaminergic drug sensitivity. Indeed, the GABAergic accumbal-ventral pallidal pathway is known to be pivotal for mediating dopamine-dependent behaviours such as basal and drug-induced locomotor activity. For example, the locomotor-enhancing effects of Amph are abolished by selective lesions of the NAc or the VP (Mele et al., 1998) , whereas pharmacological disinhibition of the VP potentiates the locomotor reaction to intra-accumbal dopamine infusions (Swerdlow and Koob, 1987) . It would, therefore, be intriguing to further test whether the PYY 3-36 -induced potentiation of dopaminergic drug sensitivity may be causally linked to altered neuronal activity in the accumbal-ventral pallidal pathway and allied neurotransmitter systems. Related to this, it would also seem relevant to extend the present findings by identifying specific GABAergic neuronal subpopulations that may be preferentially activated by PYY 3-36 .
In conclusion, our data are the first to demonstrate that peripheral administration of the Y2 receptor agonist PYY 3-36 increases the behavioural response to novelty and acute dopaminergic drug challenge in mice. Our functional investigations add to a growing body of evidence suggesting that activation of the Y2 receptor exerts stimulating effects on the mesolimbic dopamine pathways and interconnected systems (Adewale et al., 2007; Batterham et al., 2007; Stadlbauer et al., 2013a) . Thus far, activation of the Y2 receptor by PYY 3-36 has mostly been studied with respect to the control of food intake and regulation of energy homeostasis (Chandarana and Batterham, 2008; Neary and Batterham, 2009 ). More specifically, PYY 3-36 administration has been repeatedly shown to inhibit food intake in various species, including humans (Batterham et al., 2002; Chelikani et al., 2005; Koegler et al., 2005; Stadlbauer et al., 2013a) . The present data highlight that exogenous PYY 3-36 administration can regulate behavioural functions that go beyond those previously implicated in eating behaviour and energy balance. In fact, the pro-dopaminergic effects of PYY 3-36 may even contribute to its eating-inhibitory properties, possibly through a modulation of central reward processing (Narayanan et al., 2010) . Further research will thus be needed to explore whether altered neuronal activity within the mesolimbic dopamine system may be a unifying mechanism that could link the stimulatory effects of PYY 3-36 on dopamine-related behaviours with its inhibitory effects on food intake.
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